Boothbay Fund Management LLC Takes $1.28 Million Position in Alpha Cognition, Inc. (NASDAQ:ACOG)

Boothbay Fund Management LLC purchased a new stake in shares of Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 218,015 shares of the company's stock, valued at approximately $1,284,000. Boothbay Fund Management LLC owned approximately 1.36% of Alpha Cognition at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Solas Capital Management LLC acquired a new stake in shares of Alpha Cognition during the fourth quarter valued at about $8,096,000. Altium Capital Management LLC acquired a new stake in Alpha Cognition during the 4th quarter valued at approximately $1,620,000. Rosalind Advisors Inc. acquired a new stake in Alpha Cognition during the 4th quarter valued at approximately $1,489,000. ADAR1 Capital Management LLC purchased a new stake in Alpha Cognition during the 4th quarter worth approximately $1,204,000. Finally, Aristides Capital LLC acquired a new position in shares of Alpha Cognition in the 4th quarter valued at approximately $1,178,000.

Alpha Cognition Trading Down 0.6 %

NASDAQ:ACOG opened at $5.01 on Tuesday. The company has a market cap of $80.26 million, a P/E ratio of -1.96 and a beta of 2.50. The business's 50 day moving average price is $5.14. Alpha Cognition, Inc. has a 52 week low of $3.75 and a 52 week high of $7.00.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.03).

Analysts Set New Price Targets

ACOG has been the subject of a number of recent analyst reports. Raymond James raised shares of Alpha Cognition to a "moderate buy" rating in a research report on Tuesday, March 25th. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Alpha Cognition in a research report on Monday, March 31st.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Want to see what other hedge funds are holding ACOG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.